Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Before enrolling participants, each country was assigned to either cohort 1 (patients receiving only darbepoetin alfa) or cohort 2 (patients receiving any ESA). Cohort 2 was assigned only to those countries in which local regulations did not permit observational study participation by patients receiving a specific agent in a drug class.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric cancer
Expected to receive at least 8 additional weeks of a given regimen of myelosuppressive chemotherapy after enrolment
Starting treatment with either darbepoetin alfa (in Cohort 1 countries) or any ESA (in Cohort 2 countries) as per European Summary of Product Characteristics (SPC) for symptomatic anaemia.
You may not be if
Received any ESA treatment or Red Blood Cell (RBC) transfusion within 28 days prior to enrolment
Known primary benign or malignant haematologic disorder which can cause anaemia
Known hypersensitivity to ESAs
Clareo Health | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
